Get the right products to market. Own every decision that got them there.

The structure usually isn’t the problem. Portfolio review boards, Stage-Gate committees, quarterly investment reviews, monthly program reviews — most R&D organizations already have them. What breaks is the data underneath. Decisions get made in the room, then teams spend the next two weeks reconciling what was approved against what’s actually being delivered across engineering, supply, and regulatory.

Planview gives the portfolio review board, Stage-Gate sponsors, and executive R&D leadership one connected model of pipeline investments, capacity, and outcomes — pre-populated to the review, not assembled the week before. Gate decisions move from escalation to routine, the line of sight set at funding stays intact through launch, and the executive team sees what the engineering teams are running on.

These are judgment calls, and they should stay that way. What slows them down is preparing the evidence: pulling outcome trajectory, capacity consumed, and the opportunity cost of redeployed engineering talent together in one defensible view, fast enough to act on mid-flight.

Planview helps R&D leaders narrow the pipeline and keep it sharp. Thermo Fisher Scientific standardized R&D portfolio data across product development programs and cut manual reporting by up to 95%, so leadership evaluates investments faster on real-time data.

Mid-flight visibility comes from one live model, not a post-mortem rebuild. When pipeline progress, capacity, financials, and outcome data feed a single source, leadership pulls the portfolio view the morning of the review and the numbers match what engineering, regulatory, and supply are running on, with leading indicators of attainment alongside lagging results so the conversation moves from explaining variance to deciding what to do.

Planview provides that live model. NuVasive improved visibility across complex medical device development, identifying issues earlier and reducing gate-to-gate cycle time, so leadership reviews the portfolio in flight, not after launch.

Systematic adaptation depends on a model that sits above PLM, ERP, and the engineering toolchain, not another system that replaces them. Teams keep working where they work, while a connected layer of strategy, funding, capacity, and outcomes reads from those systems, so replanning happens against live data instead of in crisis mode.

Planview provides that layer, with 60+ live integrations into PLM (Teamcenter, Windchill, ENOVIA), ERP (SAP, Oracle), engineering tools, and project systems. NIO used Planview Hub to connect R&D processes across suppliers, business data, and engineering tools without replacing them, automating compliance traceability and shortening project delivery times.

Governing AI in R&D means treating agents like any other resource: with a defined scope of authority, attributed cost, and accountability to a human, plus the IP, compliance, and safety exposure that R&D uniquely carries. Agent compute and token spend has to be attributed to the pipeline program it supports, and every autonomous action needs an owner.

Planview’s agent resource management governs AI agents the same way it governs human R&D capacity, with full cost attributed to a specific pipeline program and every action accountable to a human decision-maker. The same model runs substitution scenarios across the portfolio to forecast the ROI of different human-to-agent mixes before commit.

Gartner forecasts that 40% of enterprise applications will use task-specific AI agents by end of 2026. For R&D, governing the blended workforce — and the IP, compliance, and safety exposure that comes with it — is the new portfolio job.